Retrospective analysis of sleep breathing disorders in mucopolysaccharidosis type IVA Source: International Congress 2018 – Improvements in the assessment of paediatric physiology Year: 2018
Sleep evaluation in patients with mucopolysaccharidosis type vi Source: Annual Congress 2009 - Sleep apnoea across the ages Year: 2009
Pulmonary function and exercise tolerance in glycogenosis type II (GSDII) Source: Annual Congress 2011 - Monitoring with lung function tests in airway diseases Year: 2011
Collagen I, III and IV content in airways and lung parenchyma of COPD patients Source: Annual Congress 2010 - Proteases and the matrix Year: 2010
Type II pneumocyte transplantation in ARDS Source: International Congress 2016 – Cell therapy for ARDS and sepsis Year: 2016
Pharmacological treatment of asthma in a cohort of adults during a 20-year period: results from the European Community Respiratory Health Survey I, II and III Source: ERJ Open Res, 5 (1) 00073-2018; 10.1183/23120541.00073-2018 Year: 2019
Changes in lipid metabolism in mucopolysaccharidosis (MPS) IIIA mouse lung tissue and pulmonary surfactant Source: International Congress 2017 – New insights into pathogenesis of lung disease Year: 2017
COPD assessment: I, II, III, IV and/or A, B, C, D Source: Eur Respir J 2014; 43: 949-950 Year: 2014
Sex differences in recognition of asthma in children: ISAAC Phase III Source: Eur Respir J 2005; 26: Suppl. 49, 379s Year: 2005
Sleep in type II diabetes Source: Annual Congress 2003 - Cough and sleep disorders Year: 2003
Bronchoscopy protocol for airway management in paediatric patients with mucopolysaccharidosis (mps) Source: Annual Congress 2009 - Diagnostic and interventional bronchoscopy in children Year: 2009
When IV is mandatory Source: Annual Congress 2009 - Practical Workshop - Noninvasive and invasive ventilation: looking for the right time Year: 2009
Factors affecting smear and culture conversion durations of category I, II and IV tuberculosis patients Source: Eur Respir J 2004; 24: Suppl. 48, 649s Year: 2004
Type I and III collagen protein precursors in the airways of smokers and COPD-patients Source: Annual Congress 2008 - Structural remodelling in COPD Year: 2008
HLA-class I and II genotyping in sarcoidosis patients Source: Eur Respir J 2006; 28: Suppl. 50, 354s Year: 2006
Fatigue in patients with idiopathic pulmonary fibrosis (IPF) from the pooled pirfenidone (PFD) Phase III trials Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017
Ehlers-Danlos syndrome type IV with few extrathoracic findings: a newly recognized point mutation in the COL3A1 gene Source: Eur Respir J 2002; 19: 195-198 Year: 2002
Exacerbation utilities and durations by type: estimates from Phase III benralizumab studies Source: International Congress 2017 – Biomarker-based asthma control Year: 2017
Respiratory-related sick leave-European community respiratory health survey II (ECRHS II) Source: Annual Congress 2009 - High molecular sensitisers and biological dusts Year: 2009